News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
329,636 Results
Type
Article (19733)
Company Profile (138)
Press Release (309765)
Section
Business (105255)
Career Advice (875)
Deals (18510)
Drug Delivery (93)
Drug Development (50684)
Employer Resources (79)
FDA (7653)
Job Trends (7725)
News (185632)
Policy (17305)
Tag
Academia (726)
Alliances (27783)
Alzheimer's disease (593)
Antibody-drug conjugate (ADC) (66)
Approvals (7637)
Artificial intelligence (97)
Bankruptcy (171)
Best Places to Work (5537)
Biosimilars (72)
Breast cancer (88)
Cancer (770)
Cardiovascular disease (77)
Career advice (708)
Cell therapy (113)
Clinical research (42127)
Collaboration (319)
Compensation (106)
COVID-19 (1080)
C-suite (88)
Data (802)
Diabetes (113)
Diagnostics (1730)
Drug pricing (99)
Earnings (38366)
Employer resources (73)
Events (47948)
Executive appointments (308)
FDA (8031)
Funding (226)
Gene therapy (105)
GLP-1 (527)
Government (1806)
Healthcare (5879)
Infectious disease (1137)
Inflammatory bowel disease (74)
Interviews (115)
IPO (7329)
Job creations (2431)
Job search strategy (646)
Layoffs (259)
Legal (4086)
Lung cancer (122)
Manufacturing (153)
Medical device (1953)
Medtech (1956)
Mergers & acquisitions (11309)
Metabolic disorders (386)
Neuroscience (810)
NextGen: Class of 2025 (2353)
Non-profit (905)
Northern California (828)
Obesity (248)
Opinion (179)
Patents (90)
People (33117)
Pharmaceutical (78)
Phase I (13167)
Phase II (17822)
Phase III (14331)
Pipeline (379)
Policy (78)
Postmarket research (1617)
Preclinical (4595)
Radiopharmaceuticals (157)
Rare diseases (175)
Real estate (3166)
Regulatory (12273)
Research institute (816)
Resumes & cover letters (138)
Southern California (763)
Startups (2007)
United States (7562)
Vaccines (223)
Weight loss (207)
Date
Today (67)
Last 7 days (204)
Last 30 days (987)
Last 365 days (17472)
2025 (865)
2024 (17680)
2023 (19638)
2022 (25865)
2021 (26639)
2020 (24872)
2019 (20059)
2018 (15588)
2017 (17255)
2016 (16202)
2015 (18803)
2014 (14787)
2013 (12553)
2012 (13484)
2011 (13817)
2010 (12740)
Location
Africa (406)
Asia (24633)
Australia (3168)
California (1887)
Canada (887)
China (222)
Colorado (77)
Connecticut (77)
Europe (50804)
Florida (289)
Illinois (190)
Indiana (140)
Japan (77)
Maryland (278)
Massachusetts (1596)
Minnesota (106)
New Jersey (723)
New York (540)
North Carolina (405)
Northern California (828)
Ohio (68)
Pennsylvania (444)
South America (605)
Southern California (763)
Texas (252)
Washington State (170)
329,636 Results for "mapi pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
FDA Rejects Viatris, Mapi’s Long-Acting Multiple Sclerosis Injection
With Monday’s FDA rejection of their long-acting glatiramer acetate formulation, Viatris and Mapi Pharma continue the biopharma industry’s recent losing streak in multiple sclerosis.
March 11, 2024
·
2 min read
·
Tristan Manalac
Policy
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
Viatris Inc., a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for review the companies’ recently submitted New Drug Application for GA Depot 40 mg.
August 7, 2023
·
8 min read
Mapi Pharma to Present Plans for Additional Studies of GA Depot in Multiple Sclerosis and Other Indications and Highlight Latest Results on GA Depot in Relapsing MS at the ECTRIMS-ACTRIMS® Meeting in Milan, Italy October 11-13, 2023
Mapi Pharma Ltd. announced that recent clinical data from studies of GA Depot 40 mg will be presented at the forthcoming European Committee for Treatment and Research in Multiple Sclerosis & Americas Committee for Treatment and Research in Multiple Sclerosis meeting to take place in Milan, Italy, October 11 to 13.
October 10, 2023
·
4 min read
China
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
January 7, 2025
·
6 min read
·
Annalee Armstrong
Business
Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting
Viatris Inc. and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40 mg will be presented at the American Academy of Neurology (AAN) 75th Annual Meeting in Boston taking place April 22-27.
April 24, 2023
·
6 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Deals
Two Private Equity Firms Near Potential $3B+ Deal for Mitsubishi’s Pharma Unit: Reuters
Blackstone and Bain Capital are said to be among the final bidders for the Japanese company’s Mitsubishi Tanabe Pharma, sources told Reuters Friday.
December 13, 2024
·
1 min read
·
Annalee Armstrong
Business
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.
November 27, 2024
·
9 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
1 of 32,964
Next
